- Spectral Medical Inc. (EDT) has appointed Dr. John Kellum, MD, MCCM as its Chief Medical Officer
- Dr. Kellum’s position begins March 1, 2021
- He will assume the full-time role of Chief Medical Officer at both Spectral and Dialco
- Kellum is considered one of the leading critical care researchers and world’s foremost experts on blood purification and acute kidney injury
- Spectral Medical Inc. is up 6.12 per cent to C$0.52 CAD per share
Spectral Medical Inc. (EDT) has appointed Dr. John Kellum, MD, MCCM as its Chief Medical Officer.
Spectral Medical is a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly owned subsidiary Dialco Medical Inc.
Dr. Kellum’s position begins March 1, 2021. He will assume the full-time role of Chief Medical Officer at both Spectral and Dialco, where he will be responsible for leading all medical and scientific activities, clinical activities and scientific evaluation of all partnership opportunities.
Kellum said he’s pleased to join the Spectral and Dialco teams.
“Their combined diagnostic and therapeutic approach to the treatment of septic shock is unique and I believe this represents the most likely pathway to success.”
“I look forward to helping bring new approaches to renal replacement therapy, both in the intensive care units as well as in-home. Dialco’s instrumentation offers distinctive advantages for both acute and chronic renal failure and the opportunity to improve the lives of a large number of patients,” Kellum said.
Kellum is considered one of the leading critical care researchers and world’s foremost experts on blood purification and acute kidney injury. He has pioneered research in the area of blood purification and has published original work on its application to clinical practice.
Dr. Kellum is a founding member and past president of the Acute Dialysis Quality Initiative where he developed the first widely accepted consensus definition for acute renal failure – the original manuscript has been cited over 6,000 times.
He is also a co-chair of the Kidney Diseases Improving Global Outcomes clinical practice guideline on acute kidney injury. His research has received continuous funding from the National Institutes of Health since 2001.
In addition, Dr. Kellum has served as a consultant to the FDA, the Department of Defense, the medical device industry and the pharmaceutical sector.
Spectral Medical Inc. President and CEO Dr. Paul Walker said the company is honored that Dr. Kellum has agreed to serve as its Chief Medical Officer.
“As one of the preeminent critical care researchers in the world in the field of sepsis, we expect he will be invaluable in helping complete our Tigris pivotal trial of PMX (Toraymyxin™ PMX-20R) for the treatment of patients with septic shock and endotoxemia.”
“Given his unique capabilities and relationships, Dr. Kellum will also assist us in exploring new strategic opportunities, which could include partnerships, grants or opportunistic acquisitions of complementary assets and therapies in the fields of septic shock and acute kidney disease,” Walker said.
Spectral Medical Inc. is up 6.12 per cent to C$0.52 CAD per share.
